

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

August 06, 2012

Bombay stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Kind Attn.: Mr. Kapoor
Mr. Goopalkrishnan

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad – 380 015

Kind Attn.: Mr. K. K. Mishra

Dear Sir


Re.: Press Release

We are forwarding you herewith copy of press release proposed to be published in the news papers in the matter of unaudited financial results for the quarter ended on June 30, 2012 the same may please receive in order.

Thanking you

Yours faithfully

For **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus Cadila registers 30% growth in sales in Q1

Ahmedabad, August 6, 2012

For the first quarter ended June 30, 2012, Zydus Cadila reported sales of Rs. 1547 crore, up by 30% from Rs. 1189 crore in the corresponding quarter of the previous year on a consolidated basis. The profit before tax, excluding one-time income, is up by 22% to Rs. 266 crore from Rs. 218 crore in the first quarter of 2011-12.

In the domestic formulations market, the company posted sales of Rs. 582 crores., up by 27 %. The company launched 30 new products, including line extensions, of which 10 products were the first to be launched in India.

During the quarter, the company's revenues were driven by 50 % y-y growth in the US business and a 37% growth in Brazil. Exports to the emerging markets grew by 84 %.

With the recent approval from the USFDA for its facility at Moraiya, the company expects to start getting new product approvals, which will further strengthen its US business. During the quarter, the company launched 3 products in Japan including one Day-1 launch. All three products have been developed and manufactured in India.

Further strengthening its regulatory pipeline, the company filed 9 ANDAs including 2 for injectible products, taking the cumulative number of US ANDA filings to 157. The company also filed 5 DMFs, taking the cumulative filings to 112 DMFs.

During the quarter, the company filed 11 new product dossiers and received 4 new product approvals for the European market, taking the cumulative approvals to 147 approvals. The company also filed 5 additional dossiers for the Brazilian market with the regulatory authority ANVISA and 3 additional dossiers with the regulatory authority COFEPRIS for Mexico.
